Terns Pharmaceuticals Announces the Appointment of Erin Quirk M.D. as Chief Medical Officer

SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Jan. 17, 2019 Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, announced today the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than two decades of clinical medicine and drug […]

Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

Proceeds to Support Development of Clinical and Preclinical NASH Candidates Financing Led by Vivo Capital and OrbiMed, joined by Decheng Capital Lilly Asia Ventures, the Series A investor, also investing in the Series B round SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Oct. 30, 2018 Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing […]

Mitsui Chemicals and Chitose Group Launch Novel Open Innovation Initiative to Foster Businesses and Talents

Bringing Together Unique Technologies for Joint Commercialization TOKYO–(BUSINESS WIRE)–Oct. 29, 2018 Mitsui Chemicals, Inc. (TOKYO:4183)(President & CEO: Tsutomu Tannowa) and Chitose Group (CEO: Tomohiro Fujita), a group of biotechnology startups, have jointly launched the "0 to 1 Project" as a novel open innovation initiative to foster "business and talents” based on unique technology seeds. In […]

AMPLEXOR Life Sciences Attending Annual Pharmacon Asia 2018

–(BUSINESS WIRE)–Sep. 17, 2018 AMPLEXOR: MEDIA ADVISORY: Now in its fifth year, Pharmacon Asia 2018 is one of the industry’s most highly regarded drug development and commercialization value chain events that focuses on clinical trials to market access, and addresses challenges relating to maintaining regulatory compliance. Pharmacon Asia is known for its speaker line-up and […]

JAMA Publishes Greatly Anticipated Phase III Study Using 22nd Century’s SPECTRUM® Very Low Nicotine Content Cigarettes

Immediate reduction in nicotine content is the clear winner WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–Sep. 05, 2018 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Journal of the American Medical Association (JAMA) published results of a greatly anticipated independent clinical study […]

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase I II ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 09, 2018 Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results […]

Clinigen signs agreement with Nordic Pharma for aprotinin

BURTON-ON-TRENT, England–(BUSINESS WIRE)–May. 24, 2018 Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the supply and distribution of aprotinin in a range of countries in Asia Pacific and South Africa. Aprotinin Injection belongs to a group of medicines called […]

Clean Technology and Good Manufacturing Practices to Preserve Antibiotics for Our Future Generations

Joint Workshop in Thailand by DSM Sinochem Pharmaceuticals and Indian Institute of Technology, New Delhi on Sustainable Manufacturing of Pharmaceuticals BANGKOK–(BUSINESS WIRE)–May. 09, 2018 DSM Sinochem Pharmaceuticals, global leader in sustainable antibiotics, in collaboration with the Indian Institute of Technology, New Delhi organized a workshop today on ‘Sustainability through Excellence in Manufacturing (STEM)’ to impart […]

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Rese arch

At a ceremony and symposium today, Waters Corporation (NYSE:WAT) welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute1 focused on glycobiology to participate in the Waters Centers of Innovation Program. This Smart News Release […]

LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant (eptacog beta activated)

LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital hemophilia A or B in adolescent and adult congenital hemophilia A or B patients with inhibitors, has been accepted for review by the U.S. Food and Drug Administration (FDA). The BLA contains data […]

Macrogen Launches ‘Easybox’ a Premium Temperature-Controlled Package

The precision medicine biotechnology enterprise Macrogen (CEO Hyeon-yong Jeong, www.macrogen.com)(KOSDAQ:038290) announced today its new premium temperature-controlled packaging named ‘Easybox’ for customers in the gene and genome analytics service industry worldwide. The customized premium temperature-controlled packaging option was developed by Macrogen, and its delivery speed and reliability were enhanced thanks to an express shipping service by FedEx […]